NASDAQ:SELB Selecta Biosciences (SELB) Stock Price, News & Analysis → A lot of people are making this costly mistake (From WealthPress) (Ad) Free SELB Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.88▼$1.2652-Week Range N/AVolume2.77 million shsAverage Volume979,585 shsMarket Capitalization$136.76 millionP/E RatioN/ADividend YieldN/APrice Target$2.80 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Get Selecta Biosciences alerts: Email Address Selecta Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside∞ Upside$2.80 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.99Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.33) to ($0.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.43 out of 5 starsMedical Sector541st out of 938 stocksBiotechnology Industry20th out of 41 stocks 3.3 Analyst's Opinion Consensus RatingSelecta Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.80, Selecta Biosciences has a forecasted upside of ∞ from its current price of $0.00.Amount of Analyst CoverageSelecta Biosciences has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for SELB. Previous Next 0.0 Dividend Strength Dividend YieldSelecta Biosciences does not currently pay a dividend.Dividend GrowthSelecta Biosciences does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSelecta Biosciences has received a 69.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health" and "Clinical research services for physiological diseases " products. See details.Environmental SustainabilityThe Environmental Impact score for Selecta Biosciences is -0.99. Previous Next 1.1 News and Social Media Coverage Search Interest1 people have searched for SELB on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Selecta Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Selecta Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders31.20% of the stock of Selecta Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.95% of the stock of Selecta Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Selecta Biosciences are expected to grow in the coming year, from ($0.33) to ($0.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Selecta Biosciences is -4.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaCrypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.Click to join the Crypto Community Summit Free Online Event About Selecta Biosciences Stock (NASDAQ:SELB)Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.Read More Ad DTIWarning: this could blow your mindBuckle up… ‘Cause this might shatter everything you’ve heard about “income trading”. In fact, it’s such an extreme diversion from what most people think of typical income trades that I call it: The Perfect Income Trade You see, most of the income techniques out there target a couple of percent. Maybe 5 - 10 percent if you’re lucky. But this new way of trading income on the world’s top stocks goes after more than 10x that kind of return. And here’s the best news of all: This trade can target an opportunity like that every week. Every single week. Meaning an investor has the chance to “stack up” these more aggressive income trades over and over. If that sounds interesting…Watch the presentation here SELB Stock News HeadlinesJanuary 23, 2024 | yahoo.comSelb, Germany - Weather Forecasts | Maps | News - Yahoo WeatherDecember 15, 2023 | investing.comCartesian Therapeutics Inc (RNAC)March 29, 2024 | Gold Safe Exchange (Ad)Trump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.November 14, 2023 | finance.yahoo.comFurther weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85%November 13, 2023 | bizjournals.comPared-down Selecta merges with Maryland biotechNovember 13, 2023 | msn.comSelecta Biosciences Merges With Cartesian To Focus On Autoimmune Cell TherapyNovember 13, 2023 | markets.businessinsider.comSelecta Biosciences Merges With Cartesian Therapeutics In All-stock DealNovember 11, 2023 | benzinga.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Selecta Biosciences, Inc. (NASDAQ: SELB) and Encourages Investors to Contact the FirmMarch 29, 2024 | Crypto 101 Media (Ad)Major Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.November 10, 2023 | morningstar.comSelecta Biosciences Inc SELBOctober 31, 2023 | marketwatch.comSelecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 TreatmentOctober 31, 2023 | finance.yahoo.comSelecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner SobiOctober 25, 2023 | msn.comSelecta Biosciences files for $200M mixed shelfAugust 19, 2023 | msn.comMizuho Maintains Selecta Biosciences (SELB) Buy RecommendationAugust 19, 2023 | msn.comSVB Leerink Downgrades Selecta Biosciences (SELB)August 18, 2023 | markets.businessinsider.comAnalyst Ratings for Selecta BiosciencesAugust 18, 2023 | msn.comNeedham Maintains Selecta Biosciences (SELB) Buy RecommendationAugust 18, 2023 | markets.businessinsider.comSelecta Biosciences (SELB) Gets a Buy from H.C. WainwrightAugust 17, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Buy Rating on Selecta Biosciences (SELB)August 17, 2023 | finance.yahoo.comQ2 2023 Selecta Biosciences Inc Earnings CallAugust 17, 2023 | msn.comSelecta Biosciences Narrows R&D Focus On Gout CandidateAugust 17, 2023 | finance.yahoo.comSelecta Biosciences, Inc. (SELB) Reports Q2 Loss, Misses Revenue EstimatesAugust 17, 2023 | finance.yahoo.comSelecta Biosciences Reports Second Quarter 2023 Financial Results and Updates on Strategic Initiative Designed to Maximize Stockholder Value Associated with SEL-212 EconomicsJuly 14, 2023 | finance.yahoo.comSelecta Biosciences, Inc.'s (NASDAQ:SELB) largest shareholders are individual investors with 35% ownership, institutions own 26%June 3, 2023 | finance.yahoo.comSelecta Biosciences (NASDAQ:SELB) shareholders are up 22% this past week, but still in the red over the last five yearsMay 31, 2023 | finance.yahoo.comSelecta Biosciences Announces Presentation of Data from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout During Late-Breaking Session at the EULAR 2023 European Congress of RheumatologyMay 9, 2023 | finance.yahoo.comNewsflash: Selecta Biosciences, Inc. (NASDAQ:SELB) Analysts Have Been Trimming Their Revenue ForecastsSee More Headlines Receive SELB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Selecta Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/17/2023Today3/28/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:SELB CUSIPN/A CIK1453687 Webselectabio.com Phone(617) 923-1400Fax617-924-3454Employees64Year FoundedN/APrice Target and Rating Average Stock Price Target$2.80 High Stock Price Target$5.00 Low Stock Price Target$1.00 Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$35.38 million Net Margins-72.04% Pretax Margin-73.23% Return on Equity-44.13% Return on Assets-22.00% Debt Debt-to-Equity Ratio0.21 Current Ratio4.18 Quick Ratio4.18 Sales & Book Value Annual Sales$110.78 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow9.91 Book Value$0.61 per share Price / BookN/AMiscellaneous Outstanding Shares155,200,000Free Float106,780,000Market Cap$136.76 million OptionableOptionable Beta0.84 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Carsten Brunn Ph.D. (Age 52)CEO, President & Director Comp: $914.66kMr. Blaine T. Davis (Age 49)Chief Financial Officer Comp: $370.34kDr. Lloyd Johnston Ph.D. (Age 55)Chief Operating Officer Comp: $589.81kDr. Takashi Kei Kishimoto Ph.D. (Age 63)Chief Scientific Officer Comp: $599.81kDr. Peter G. Traber M.D. (Age 68)Chief Medical Officer Comp: $670.29kDr. Ulrich H. von Andrian-Werburg M.D.Ph.D., Co-Founder and Co-Chair of the Scientific Advisory BoardMr. Matthew Bartholomae J.D.General Counsel & SecretaryMs. Kristen BaldwinChief People OfficerMs. Ann K. Donohue CPA (Age 41)VP of Finance & Controller Comp: $286.97kMore ExecutivesKey CompetitorsClearside BiomedicalNASDAQ:CLSDMediWoundNASDAQ:MDWDImmunicNASDAQ:IMUXTelomir PharmaceuticalsNASDAQ:TELOTheseus PharmaceuticalsNASDAQ:THRXView All CompetitorsInsiders & InstitutionsCitadel Advisors LLCSold 800 shares on 2/15/2024Ownership: 0.000%Simplex Trading LLCSold 400 shares on 2/2/2024Ownership: 0.000%Carsten BrunnSold 2,932 sharesTotal: $3,107.92 ($1.06/share)Peter G TraberSold 705 sharesTotal: $747.30 ($1.06/share)View All Insider TransactionsView All Institutional Transactions SELB Stock Analysis - Frequently Asked Questions Should I buy or sell Selecta Biosciences stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Selecta Biosciences in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SELB shares. View SELB analyst ratings or view top-rated stocks. What is Selecta Biosciences' stock price target for 2024? 6 brokerages have issued 1 year target prices for Selecta Biosciences' stock. Their SELB share price targets range from $1.00 to $5.00. On average, they anticipate the company's stock price to reach $2.80 in the next twelve months. View analysts price targets for SELB or view top-rated stocks among Wall Street analysts. How were Selecta Biosciences' earnings last quarter? Selecta Biosciences, Inc. (NASDAQ:SELB) announced its quarterly earnings data on Thursday, August, 17th. The company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.12) by $0.05. The firm had revenue of $5.25 million for the quarter, compared to analyst estimates of $9.90 million. Selecta Biosciences had a negative net margin of 72.04% and a negative trailing twelve-month return on equity of 44.13%. What other stocks do shareholders of Selecta Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Selecta Biosciences investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Novavax (NVAX), Dynavax Technologies (DVAX), Geron (GERN), Catalyst Pharmaceuticals (CPRX) and TherapeuticsMD (TXMD). When did Selecta Biosciences IPO? Selecta Biosciences (SELB) raised $64 million in an initial public offering on Wednesday, June 22nd 2016. The company issued 4,300,000 shares at a price of $14.00-$16.00 per share. UBS Investment Bank and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Needham & Company were co-managers. Who are Selecta Biosciences' major shareholders? Selecta Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.00%), Concourse Financial Group Securities Inc. (0.00%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Carrie Smith Cox, Carsten Brunn, Kevin Tan, Lloyd P Johnston, Nishan M Desilva, Peter G Traber, Timothy A Springer, Timothy C Barabe and Timothy C Barabe. View institutional ownership trends. This page (NASDAQ:SELB) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the MarketsBill Gates is all about this tiny $2 stockTimothy SykesThe 3rd Revolution in WarfareWeiss RatingsFed launches fourth dollar overhaulStansberry ResearchAI to Meet the Same Fate as EVs? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Selecta Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.